China Infrastructure (CHNC)

https://www.otcmarkets.com/stock/CHNC/profile 

The Company operates through three wholly owned subsidiaries. Through Hippocrates Direct Healthcare, LLC, a Texas limited liability company (“HDH”), formed on September 11, 2017, the Company offers concierge medicine at an affordable price through its membership-based model. Through Precision Research Institute, LLC, a Texas limited liability company (“PRI”) formed on May 18, 2016, the Company provides services in therapeutic areas of clinical trials, Through Pharmacology University, Inc., a Delaware corporation (“PUI”), incorporated on January 7, 2017, the Company provides educational systems focused on medicinal cannabis, in cities throughout the United States of America and six countries in Latin America. Information regarding the acquisition of these subsidiaries is as follows:

Acquisition of HDH and Recapitalization

On December 14, 2017, the Company, a wholly owned subsidiary of the Company and HDH entered into a Plan and Agreement of Merger (the “HDH Merger Agreement”), which provided that the subsidiary would be merged with and into HDH and that the two holders of units in HDH would receive shares of the Company’s common stock or cash, as each of them elected. On February 5, 2018 (the “Effective Date”), the merger was consummated, as the result of which HDH became the wholly owned subsidiary of the Company and the Company issued 4,500,000,000 shares of its common stock to one of the holders of units in HDH and made a promissory note for $9,500 in favor of the other, in accordance with their elections. Pursuant to the HDH Merger Agreement, the sole director, officer and majority stock-holder of the Company resigned from these positions, surrendered all of his shares of common stock in the Company and cancelled all of its indebtedness to him in consideration of a promissory note made by the Company in his favor in the principal amount of $420,000. (For information about this note, see Note 5.)

The merger whereby the Company acquired HDH was a reverse merger that resulted in a change of control, and has been accounted for as a recapitalization, whereunder HDH is the accounting acquirer. Accordingly, the historical financial statements prior to the Effective Date are those of HDH, have been prepared to give retroactive effect to the merger and represent the operations of HDH. The consolidated financial statements include the balance sheets of both companies at historical cost, the historical results of HDH and the results of the Company from the Effective Date. All share and pershare information in the accompanying unaudited consolidated financial statements and these notes has been retroactively restated to reflect the recapitalization.

https://twitter.com/hippocratesinc?lang=en

On December 19, 2019, the Company acquired Pharmacology University, Inc., a Delaware corporation (“PUI”), pursuant to an Agreement and Plan of Merger, dated as of November 7, 2019, under which PUI was merged with and into the Company (the “PU Merger Agreement”). Pursuant to this agreement, the Company is obligated to issue, to the former holders of the common stock of PUI, 4,875,000,000 shares of the Company’s common stock and 2,000,000 shares of its Series A Convertible Preferred Stock. These shares are expected to be issued in the near future. When the shares are issued, a change of control will occur. In a separate agreement, Ms. Elizabeth Hernandez, the holder of 4,500,000,000 shares of Common Stock, and the president, sole director and controlling stockholder of the Company agreed to sell 3,000,000,000 such shares to the Company pursuant to a Stock Purchase Agreement, dated November 7, 2019, between the Company and her (the “Hernandez SPA”).
 

FaceBook - https://m.facebook.com/PrecisionResearchInstituteLLC/

Twitter - https://twitter.com/pri_center?s=11

Top of page B-11 https://backend.otcmarkets.com/otcapi/company/financial-report/256967/content

Acquisition of PRi had taken place on 31 March, 2019

Acquisition of Precision Research Institute, LLC On March 31, 2019, the Company acquired all of the outstanding units in Precision Research Institute, LLC, a Texas limited liability company (“PRI”) formed on May 18, 2016, from the Company’s then president.

 Bottom of Page B-5 https://backend.otcmarkets.com/otcapi/company/financial-report/256967/content

Merger with Pharmacology University, Inc.

https://www.facebook.com/pg/pharmacologyuniversity/about/?ref=page_internal

A/S  20,000,000,000   09/30/2020

O/S    8,732,256,416   09/30/2020

Restricted 7,023,693,512   09/30/2020

Unrestricted 1,708,562,904  09/30/2020